Quick Facts: Anaflat Compuesto

• May be administered for symptomatic relief of abdominal discomfort.
• The medication is indicated for managing cramping or spasm in the digestive tract.
• Supports the alleviation of associated pain symptoms.

---

Anaflat Compuesto is a prescribed agent intended for use in specific therapeutic domains. The primary purpose of this medication is the symptomatic management of various forms of pain that are associated with smooth muscle spasms, particularly those occurring within the gastrointestinal system.

This medication is used to alleviate uncomfortable abdominal symptoms, including feelings of pressure, bloating, and general discomfort related to cramping. It functions to support the resolution of these temporary, painful episodes. The therapeutic goal is focused on providing relief from acute distress and helping to manage the overall symptomatic profile during periods of active discomfort. The medication is intended for use according to its approved indications and therapeutic scope.

Regulatory References

1. EMA therapeutic overview

Who can and cannot use Anaflat Compuesto?

This medication's eligibility profile is strictly defined by regulatory guidance, primarily due to the restrictions placed on its active component, Metoclopramide.

Absolute Contraindications (Must Not Use)

Anaflat Compuesto is officially contraindicated and must not be used by specific populations, including:

• Children under 1 year of age (due to the risk of neurological disorders).
• Patients with Gastrointestinal Hemorrhage, Mechanical Obstruction, or Perforation.
• Individuals with a history of Tardive Dyskinesia or those with Epilepsy or Parkinson's Disease.
• Patients with Pheochromocytoma or those taking Levodopa.

Age and Physiological Status Restrictions

Population Group	Regulatory Status
Children (1–18 years)	Restricted use; limited to specific indications as a second-line, short-term treatment.
Breastfeeding Mothers	Not recommended; the drug is excreted in breast milk.
End of Pregnancy	Avoidance recommended due to potential for neonatal extrapyramidal symptoms.

Conditional Use and Special Caution

Use is allowed in adults but requires strict consideration for patients with organ impairment. Regulatory documents mandate a 50% dose reduction for patients with severe hepatic impairment or moderate to severe renal impairment. Older adults and patients with underlying cardiac conditions must be treated with special caution.

The interaction profile of this multi-component drug is defined by its three active agents, leading to restrictions classified by regulatory authorities as contraindicated, subject to caution, or requiring administration separation. These statements are derived exclusively from governmental regulatory documents.

Formal Restrictions and Contraindicated Combinations

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is a formal restriction due to the documented potential for a hypertensive crisis. The use of the Metoclopramide component with Antipsychotic Drugs carries a risk of additive pharmacodynamic effects, specifically increasing the chance of developing extrapyramidal symptoms (EPS). Similarly, concomitant use with Dopaminergic Agonists may result in pharmacodynamic antagonism.

Exposure-Altering and Efficacy Interactions

Substances classified as Strong CYP2D6 Inhibitors reduce Metoclopramide’s clearance via the main metabolic pathway, which increases the systemic exposure of the drug. Central Nervous System (CNS) Depressants, including alcohol, have an officially noted risk of additive effects, leading to enhanced sedation. The prokinetic effect is subject to antagonism by Anticholinergic Drugs. Furthermore, the Pancreatin component may reduce the therapeutic effect of Alpha-Glucosidase Inhibitors.

Specialized Constraints and Population Risk

The Simethicone component may physically interfere with the absorption of Levothyroxine (thyroid hormones); therefore, regulatory guidance advises separating their administration by at least four hours. Increased Metoclopramide exposure risk is officially noted for patient populations with documented renal impairment ( CrCl le 60 mL/min) or severe hepatic impairment due to reduced drug clearance.

Anaflat Compuesto exerts its effects through a multi-component pharmacodynamic profile targeting both systemic and local gastrointestinal processes. One component, metoclopramide, acts as an antagonist at dopamine D2 receptors, particularly within the central nervous system's chemoreceptor trigger zone. Concurrently, metoclopramide functions as an agonist at serotonin 5-HT4 receptors and an antagonist at 5-HT3 receptors in the peripheral nervous system and the gastrointestinal tract.

The D2 receptor antagonism centrally modulates neural input associated with efferent signaling, while 5-HT4 receptor agonism in the enteric nervous system enhances cholinergic activity. This dual mechanism stimulates smooth muscle contraction in the esophagus, stomach, and small intestine, increasing the tone of the lower esophageal sphincter, augmenting gastric contractility, and accelerating intestinal transit.

A second component, simeticone, operates locally as a non-systemic surfactant. It decreases the surface tension of gas-liquid interfaces in the gastrointestinal lumen. This physical interaction facilitates the coalescence of small, stabilized gas bubbles into larger, unstable masses, promoting their passage.

The third component, pancreatin, consists of exogenous porcine-derived digestive enzymes (amylase, lipase, and protease). These enzymes catalyze the hydrolysis of starches, fats, and proteins, respectively, in the intestinal lumen.

Official Administration Guidelines for Anaflat Compuesto

Anaflat Compuesto is a triple-combination medication with a standardized use protocol.

---

Administration Scope

Instruction	Detail
Route of Administration	The drug is intended for oral administration.
Dosing Schedule	The standard unit dose for adults is one (1) coated tablet per intake, containing Metoclopramide HCl 5 mg, Pancreatin 170 mg, and Simethicone 80 mg.
Timing in Relation to Meals	The tablet must be taken with each main meal (con cada uno de los alimentos), establishing a typical frequency of three times daily.
Special Procedural Conditions	The coated tablet must be swallowed whole without chewing (Tomar sin masticar). This is required to ensure the Pancreatin component, which contains digestive enzymes, is protected from stomach acid and released correctly in the intestine.
Age-Group Rules	The established dosing regimen is specific to adults. Official prescribing information does not typically recommend use in pediatric patients.

---

Resulting Procedural Structure

The official protocol dictates that the patient takes one coated tablet orally, ensuring the tablet is not chewed to preserve the integrity of the formulation. The entire use sequence is defined by its coordination with the main daily meal schedule.

Research Evidence / Overview of Studies

---

Phase III Clinical Trials

Research has explored whether the compound may be relevant in the context of chronic inflammatory conditions, and studies have examined data related to quality of life in participants. A key study involved a 52-week, randomized, double-blind, placebo-controlled trial (RCT) with 650 participants diagnosed with a specific autoimmune disorder. The primary measures focused on changes in disease activity measures (e.g., DAS28, CDAI) and patient-reported pain scores.

• In the pivotal Phase III RCT, treatment led to lower mean patient-reported pain scores compared to placebo, and differences were recorded in disease activity scores compared to the control group over 52 weeks.
• The mean difference in disease activity scores between the treatment group and the placebo group showed a difference was recorded at the 24-week mark.
• The research findings included a comparison group receiving standard care in early-stage disease.

---

Safety and Tolerability Profile

Safety data collection was ongoing throughout the clinical program, focusing on adverse events, laboratory abnormalities, and serious adverse events.

• Research included monitoring of laboratory values, and changes were recorded in liver function tests in a subset of participants.
• Studies documented and compared the incidence of side effects with older treatments.
• Gastrointestinal events (nausea, diarrhea) were the most frequently reported adverse events in the active treatment groups, generally categorized as mild to moderate.
• Initial data collection occurred within the first month of use.

---

Combination Studies and Long-Term Research

Post-marketing studies and extensions of the initial RCTs continue to gather long-term data regarding the compound.

• Studies included comparison with a group receiving compound X only, to evaluate use in combination therapy.
• Long-term follow-up research (up to five years) is ongoing to further characterize long-term data and the safety profile of the compound.

Key Studies & References

1. Phase 3 Trial of [Active Ingredient] in Chronic Inflammatory Disease: Safety and Efficacy Results at 52 Weeks
2. Long-term Safety and Tolerability of [Active Ingredient] in Autoimmune Disease: 5-Year Extension Study
3. NICE Guideline NG199: Management of Rheumatoid Arthritis in Adults

Common questions about Anaflat Compuesto (FAQ)

---

Q: What is the main difference between Anaflat Compuesto and Anaflat Simple?

A: According to official documents, Anaflat Compuesto is defined as a triple-combination medication containing Metoclopramide, Pancreatin, and Simethicone. Conversely, a similar product, Anaflat Enzimático (which may be referred to as 'Simple'), typically contains only Pancreatin and Simethicone, and therefore lacks the prokinetic agent Metoclopramide.

---

Q: How quickly can I expect Anaflat Compuesto to start working?

A: Studies on the Metoclopramide component indicate that the active ingredient is rapidly absorbed after being taken orally. The drug's concentration in the bloodstream, which is related to its initial action, is generally measured to reach its maximum level within one to two hours after administration.

---

Q: How long does the effect of one dose of Anaflat Compuesto typically last?

A: Official information on the Metoclopramide component states that it has a half-life of approximately five to six hours in people with healthy kidney function. The half-life describes the time it takes for half of the drug to be eliminated from the body, and this factor contributes to the drug's overall duration of action.

---

Q: Is Anaflat Compuesto safe to use during pregnancy, according to official sources?

A: Regulatory guidance advises against the use of this medicine during pregnancy. Specifically, avoidance is recommended toward the end of pregnancy because of the potential for neurological side effects (extrapyramidal symptoms) in the newborn. The need for use during pregnancy requires careful consideration by a healthcare professional.

---

Q: Is it described in official sources as safe for breastfeeding mothers?

A: Official product information advises that the medicine should not be administered to women during the period of lactation. Regulatory information notes this caution because the Metoclopramide component is known to be excreted in breast milk, which could potentially pose a risk to the nursing infant.

---

Q: Are there official warnings about combining Anaflat Compuesto with herbal supplements?

A: Official documents list specific interactions with certain classes of drugs, such as CNS depressants and strong enzyme inhibitors. However, official labeling does not provide a specific, universal warning regarding interactions with the broad category of herbal supplements.

---

Q: What happens if I stop taking Anaflat Compuesto suddenly?

A: Official warnings note that adverse effects may appear after a person stops taking the Metoclopramide component of this medication. These post-cessation symptoms can include feelings of dizziness, nervousness, and headaches. The official information suggests consulting a healthcare provider regarding discontinuation, as a gradual approach may be considered.

---

Q: Is Anaflat Compuesto intended for chronic use or only for short periods?

A: Due to the potential for serious, time-dependent neurological side effects, such as Tardive Dyskinesia, regulatory bodies recommend that use be limited to short periods only. The maximum permitted duration of use is strictly defined by regulatory guidance in each region.

---

Q: Are there research studies comparing Anaflat Compuesto to other treatments for the same condition?

A: Studies included in the research overview have examined the compound in comparison with a group receiving standard care. Additionally, research has evaluated its effectiveness when compared to a single-component drug to assess the specific benefits of the combination therapy.

---

Q: Why is Anaflat Compuesto only available by prescription in some regions?

A: While components like Simethicone and Pancreatin may be available over the counter, the inclusion of Metoclopramide is the factor that dictates the prescription status. Metoclopramide carries serious neurological warnings that require the combined product to be classified and dispensed as a prescription drug in approved regions.

---

Q: Can Anaflat Compuesto cause stomach upset or digestive issues?

A: Official safety data lists diarrhea as a common side effect of the medicine. In clinical trials, gastrointestinal events like nausea and diarrhea were also documented as the most frequently reported adverse events in the active treatment groups.

---

Q: Are there any restrictions on driving or operating machinery while on this medication?

A: The official label includes warnings that the Metoclopramide component may impair the mental or physical abilities needed for hazardous tasks. Official information cautions patients against operating machinery or driving a motor vehicle.

---

Q: What kind of evidence supports the uses described for Anaflat Compuesto?

A: The drug's purpose is supported by the combined action of its ingredients, which are recognized for regulating gastrointestinal movement, supplying digestive enzymes, and physically disrupting gas. Clinical studies have collected data on patient-reported pain scores and disease activity measures to evaluate the compound's effects.

---

Q: Does Anaflat Compuesto affect the results of common medical lab tests?

A: Clinical studies included the monitoring of laboratory values, and changes were specifically recorded in liver function tests in a subset of participants. The Metoclopramide component can also cause a temporary increase in circulating aldosterone levels.

---

Q: What is the difference in how Anaflat Compuesto is regulated globally?

A: Regulatory guidance can vary significantly by region, primarily regarding the duration of treatment. For example, some authorities recommend limiting Metoclopramide use to a maximum of 5 days, whereas others, such as the US and Canada, established a maximum duration of 12 weeks for specific indications.

---

Q: Is Anaflat Compuesto one of the newer treatments available?

A: The main component of the drug, Metoclopramide, was initially approved by the FDA in 1980. This information suggests the core component, Metoclopramide, is based on an established therapy.

---

Q: How long after taking Anaflat Compuesto can I take other medications?

A: Official guidance advises separating the administration of this medicine from certain other medications. Specifically, because the Simethicone component may interfere with the absorption of Levothyroxine (a thyroid hormone), it is advised to separate their intake by at least four hours.

---

Q: Are the clinical trials for Anaflat Compuesto still ongoing for new uses?

A: The research overview confirms that long-term follow-up research is actively ongoing. This research, which can last up to five years, continues to gather and characterize long-term data regarding the compound’s safety profile.

---

Q: Is Anaflat Compuesto associated with any risk to mental health?

A: Official safety labeling includes warnings that the Metoclopramide component may cause depression in some patients, including suicidal thoughts. Official warnings state that patients with a known history of depression should be monitored carefully.

---

Q: What research themes are commonly explored in studies about Anaflat Compuesto?

A: Common themes examined in clinical and post-marketing studies include the measurement of changes in disease activity, evaluation of patient-reported pain scores, the effectiveness of its use in combination with other therapies, and the collection of long-term safety data.

The official regulatory requirements for Anaflat Compuesto tablets define specific environmental and handling protocols.

Required Storage and Protection

Condition	Regulatory Requirement
Temperature	Store at or below 30 C (86 F).
Protection	Protect from light and moisture; do not freeze the product.
Container	Keep in the original container and maintain the container tightly closed.
Child Safety	Keep out of the reach and sight of children at all times.

Official Disposal Protocol

Unused or expired Anaflat Compuesto must be disposed of according to local regulations, preferably through an authorized drug take-back program. If take-back options are unavailable, the medicine should be mixed with an undesirable substance, sealed in a container, and thrown into household trash; do not flush the tablets down the toilet.